June 27, 2022
It didn’t have the brand recognition of Abbott, or the billions of the medical technology multinational Becton Dickinson. Before the pandemic hit, Cue Health didn’t even have a product on the market. What the fledgling company did have in July 2020 was a deal to provide its newly authorized Covid-19 test for the National Basketball Association’s highly publicized bubble.
With the imprimatur of the NBA, Cue rocketed from startup obscurity to primetime fame.
“If it’s good enough for LeBron, we want to democratize it and make sure it’s available to the American people,” said Admiral Brett Giroir, the leader of the Trump administration’s testing efforts, in an October 2020 announcement of a $481 million deal to flood the country with Cue’s Covid-19 tests.
About the Author
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.